Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swallowed and taken independent from meals.

A simple dosage scheme like valproate sustained release minitablets once daily in the evening should improve the compliance and likely the seizure situation of the patients. The data of this non interventional trial were directly extracted from the physician's electronic patient database. The observational period was 7 weeks compared to a retrospective period 7 weeks before start of the study.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Desitin Arzneimittel GmbH
• Treatments: Valproic Acid

Criteria

Inclusion Criteria:

• age of 12 years and above

• epilepsy patients

• indication to initiation / conversion to valproate sustained release minitablets once daily

Exclusion Criteria:

• contraindication to valproate use

• no indication for conversion to valproate sustained release minitablets once daily